Hims & Hers Health prints Q1 results on June 11 with the most consequential positioning tension of the year: a short book that refuses to budge despite a month of covering, a borrow market with literally no room left, and a stock that has clawed back 5% this week to $28.98.
The lending picture is about as extreme as it gets. Availability has been at zero percent every single session tracked over the past 30 days — every share in the lending pool is out on loan — and cost to borrow has jumped 32% in a week to 1.29%, its highest level since April. Short interest is 27.9% of the free float, down from a peak near 30% in early May, but still one of the heavier short books among mid-cap health care names. The ORTEX short score holds at 68.7, near the top of its recent range, and the utilization rank sits in the 3rd percentile of the broader universe. Shorts have trimmed — about 9 million shares have been covered over the past month — but the pace has slowed sharply this week, with only around 1.3 million shares covered in the last five days. This is not a crowded exit; it looks more like a patient, dug-in short base that has chosen not to chase the stock higher.
Options positioning has returned to neutral, which is itself a meaningful shift from where this story stood a week ago. The put/call ratio is 0.59, sitting essentially on top of its 20-day average of 0.59, with a z-score near zero. That is a notable normalisation: the prior note documented a PCR of 0.52 — the lowest reading of the past 52 weeks — as call buyers flooded the market ahead of earnings week. The pullback toward neutral suggests that wave of bullish options activity has largely been expressed, absorbed into the stock's 5% weekly gain. Into the actual print, options traders are neither adding to upside bets nor hedging aggressively. The setup is balanced on the options side, which throws the focus squarely onto the binary of the earnings result itself.
The Street is divided, and recent analyst activity underscores that tension. B of A Securities has cut its target three times since mid-May, landing at $25 — below the current price — while maintaining a Neutral rating. JPMorgan held its Overweight but trimmed to $33 after the May print. Truist moved the other way, raising its Hold target to $23 from $18. The mean price target is $26.61, modestly below where the stock trades at $28.98, which means the consensus is not pricing in much further upside from here. Bulls point to the Novo Nordisk partnership, a 2030 revenue build-out, and a 12-month forward EPS growth rate that ranks in the 90th percentile of the universe. Bears point to the compounding business facing regulatory pressure, margin headwinds as the company invests in the GLP-1 market, and competition from larger, better-capitalised rivals. The forward P/E has expanded sharply over the past month — up roughly 25 turns to 48.9x — reflecting how much of the bull case the stock has already priced in ahead of the result.
The earnings history here warrants attention. The May 11 print produced an 11.5% single-day drop and a 21% five-day decline — the worst reaction in recent memory. The prior quarter, by contrast, saw a 4% dip followed by a 6% recovery over five days. Two data points do not form a pattern, but they do confirm that this stock moves hard on results, in both directions, and that the May episode established a new reference point for how punishing a miss can be with a 28% short base standing ready.
The June 11 print is therefore less about the headline revenue number and more about whether management can credibly reassure the market on compounding economics, GLP-1 competitive dynamics, and the path to margin — with shorts holding their ground and the stock trading above the analyst consensus.
See the live data behind this article on ORTEX.
Open HIMS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
